Effect of high calcium and phosphorus intake on mineral retention in very low birth weight infants chronically treated with furosemide.
The treatment of premature infants with the diuretic furosemide appears to be a contributory factor in the development of metabolic bone disease presumably because of furosemide-induced hypercalciuria. In this study, we measured calcium and phosphorus balance in furosemide-treated very low birth weight infants (VLBW) infants with bronchopulmonary dysplasia (BPD) who were fed a specialized premature formula containing increased amounts of calcium and phosphorus. Furosemide-treated infants received 166 +/- 37 mg/kg/day and retained 80 +/- 34 mg/kg/day of calcium, and 87 +/- 19 mg/kg/day and retained 52 +/- 14 mg/kg/day of phosphorus. The amounts retained were approximately 65% of the calcium and 72% of the phosphorus requirements for in utero mineral accretion. Compared to a group of similarly fed VLBW infants without BPD and not treated with the diuretic, the furosemide-treated infants excreted a larger percent of the calcium intake in the urine but had similar total urinary calcium and phosphorus losses (mg/kg/day) and serum calcium, phosphorus, alkaline phosphatase, and parathyroid hormone (PTH) levels. From the latter two findings, we suggest that the extra mineral content of the formula may have promoted bone mineralization and prevented the occurrence of secondary hyperparathyroidism.
Rowe
J C
JC
Department of Pediatrics, University of Connecticut Health Center, Farmington 06032.
Carey
D E
DE
Goetz
C A
CA
Adams
N D
ND
Horak
E
E
D002118:Calcium / Q000008:administration & dosage / Q000378:metabolism*; D005069:Evaluation Studies as Topic; D005527:Food, Fortified; D005665:Furosemide / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007230:Infant, Low Birth Weight / Q000378:metabolism*; D007231:Infant, Newborn; D010758:Phosphorus / Q000008:administration & dosage / Q000378:metabolism*
D010758:Phosphorus; D005665:Furosemide; D002118:Calcium